Financial Consulate’s PharmaCyte Biotech PMCB Stock Holding History

Financial Consulate’s Portfolio PMCB Stock Details PMCB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2	Hold	2	–	–	﹤0.01%	1401
2025 Q4	$2	Hold	2	–	–	﹤0.01%	1338
2025 Q3	$2	Buy	+2	New	+$2	﹤0.01%	1151

Other funds holding PMCB

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Financial Consulate's PMCB Position: Q1 2026 in Review

Financial Consulate held its PharmaCyte Biotech (PMCB) position steady in Q1 2026 at 2 shares worth $2. The position accounts for ﹤0.01% of the portfolio, ranked #1401.

Financial Consulate first reported a position in PMCB in Q3 2025 and has held it in 3 quarters since. 32 funds tracked by Wall St. Rank hold PMCB as of Q1 2026.

Financial Consulate held 2 shares of PharmaCyte Biotech worth $2 as of Q1 2026.
Financial Consulate left its PharmaCyte Biotech share count unchanged in Q1 2026.
PharmaCyte Biotech made up ﹤0.01% of Financial Consulate's portfolio in Q1 2026, its #1401 holding.
Financial Consulate first reported a position in PharmaCyte Biotech in Q3 2025 and has held it in 3 quarters since.
32 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q1 2026.

Based on Financial Consulate's 13F filing for Q1 2026, filed 21 Apr 2026.